On 10 June 2026, Lifecare announced successful completion of its first six-month implant evaluation, including no observations of clinically significant adverse events, foreign body reactions or other observable clinical effects during the implantation period. The independent histological analysis now confirms those clinical observations.

The findings are consistent with earlier stages of the LFC-SEN-002 study, where histological analyses following 12-week implantations similarly demonstrated favorable tissue response without evidence of adverse biological effects. The latest results therefore extend Lifecare's documented in-vivo biocompatibility experience from 12 weeks to six months.

The pathology assessment confirms a favorable tissue response following six months of continuous implantation and further supports Lifecare's growing body of evidence regarding long-term implant biocompatibility.

“These results further strengthen our confidence in the long-term biocompatibility of the Lifecare implant platform,” said Joacim Holter, Chief Executive Officer of Lifecare ASA.

“We have now extended favorable biopsy and pathology findings from 12 weeks to six months while continuing to observe only limited and expected local tissue response. Combined with the previously reported operational performance of the implant, these findings represent another important step in de-risking our technology platform and another important step in de-risking our technology platform and strengthening the foundation for future clinical and commercial execution.”

The results further support Lifecare's development program for both veterinary and human applications and strengthen the biological validation of the company's long-term implant platform.

The histological examination of tissue samples collected at explantation demonstrated normal connective tissue, adipose tissue and vascular structures surrounding the implantation site. The assessment identified only limited localized inflammatory response and mild fibrosis, with no findings indicative of clinically significant foreign body reaction, implant rejection, extensive inflammatory response or other adverse biological tissue effects.

The pathology findings follow Lifecare's announcement on 10 June 2026 that the company's first six-month implant remained operational throughout the implantation period, continued to communicate with external equipment following explantation, and showed no visible mechanical damage upon microscopic inspection. The company also reported no clinically significant adverse events, foreign body reactions or other observable clinical effects during the six-month implantation period.

The explanted implant will undergo laboratory evaluation, including assessment of sensor performance, chemistry status, membrane condition and long-term implant durability following six months in vivo.

Two additional implants manufactured from the same reproducible production batch remain active in the ongoing study and continue to progress toward similar implantation durations, providing further opportunity to evaluate repeatability and long-term performance.

The results generated through LFC-SEN-002 continue to provide important input supporting Lifecare's product development, manufacturing scale-up activities, regulatory pathway and future commercialization plans.

About LFC-SEN-002
LFC-SEN-002 is an ongoing longevity and performance study evaluating Lifecare's implantable CGM technology in dogs. The study focuses on biocompatibility, system stability and in-vivo signal behaviour and supports both veterinary product development and future human clinical programs. The study is conducted under veterinary supervision in cooperation with the Faculty of Veterinary Medicine, Department of Companion Animal Clinical Sciences at the Norwegian University of Life Sciences (NMBU).